Positive results prompt AstraZeneca to end Crestor trial

03/31/2008 | Wall Street Journal (free content), The · USA Today

AstraZeneca on Monday announced it will halt a trial of Crestor earlier than scheduled after results showed the cholesterol-lowering drug had significant advantages over placebo. The study found Crestor effective in lowering the risk of major cardiovascular events in patients with high levels of C-reactive protein, which has been associated with heart problems.

View Full Article in:

Wall Street Journal (free content), The · USA Today

Published in Brief:

SmartBrief Job Listings for Health Care